CPT-11 is a DNA topoisomerase I inhibitor, derived from Camptothecine (CPT), which acts in vivo as a prodrug and is converted to SN-38 by a carboxylesterase. SN-38 is considered to be responsible for both the antitumoral activity and the toxicity of CPT-11 [1] .
The SN-38 plasma concentrations reflect both the rate of CPT-11 metabolization and the rate of SN-38 elimination, which is mainly through conjugation by hepatic uridine diphosphate glucuronosyltransferases (UGTs) to the glucuronide (SN-38G) derivative.
Glucuronidation seems an important variable in the determination of activity as well as in the toxicity. Recently, Gupta et al. [2] demonstrated, in a murine model, that UGT may be a site of modulation (induction-inhibition) of the SN-38 clearance with relevant pharmacokinetic consequences. They have proposed a SN-38 biliary index [3] with moderate predictive value of severe diarrhea when CPT-11 is administered weekly. Patients with biliary index values ^ 4000 had a significantly higher risk of grade 3-4 diarrhea.
It has been recently shown that the UGT* 1.1 isozyme, which glucuronidates bilirubin, is also the isoform responsible for SN-38 glucuronidation [4] .
Individuals with Gilbert's syndrome have deficient UGT* 1.1 activity. This inherited disorder, characterized by abnormal bilirubin glucuronidating activity, presents mild, chronic, unconjugated hyperbilirubinemia [5] .
UGT deficiencies are asssociated with changes in drug disposition of molecules such as acetaminophen, leading to enhanced toxicity as a result [6] . Thus, patients with Gilbert's syndrome may be at an increased risk for CPT-11 related toxicity. The two present case reports of severe CPT-11 toxicity in Gilbert's syndrome patients, underline the key role of SN-38 glucuronidation for CPT-11 toxicity and are the first clinical evidence linking bilirubin glucuronidation status and CPT-11 related toxicity. They call for innovative approaches for both prediction and monitoring of CPT-11 induced clinical toxicity.
Both observations were done during the early steps of an ongoing phase I trial, which included pharmacokinetics, of the Oxaliplatin and CPT-11 combination regimen sequentially, given i.v. on the same day every three weeks [7] .
Patients and methods
Patient A, a 49-year-old italian woman with liver and lung metastases arising from colon cancer had progressed on two previous fluoropyrimidine based regimens. Blood tests available in the prior five years exhibited asymptomatic mild unconjugated hyperbilirubinemia (range 19-38 umol/1) coincident with episodes of gastroenteritis or 5-FU based chemotherapy. At the inclusion in the Oxaliplatin/CPT-11 trial, her baseline bilirubin and other liver parameters were normal, without evidence of hemolysis (normal reticulocytes and haptoglobine, no schistocvtes). After the first cycle of Oxaliplatin and CPT-11, given at 85 mg/m 2 and 150 mg/m 2 respectively, the patient presented a rise in bilirubin level, predominantly unconjugated. The bilirubin increase began on day two (total bil 20 umol/1), reached a maximal value on day 6 (39 umol/1), and returned to normal values on day 13 (16 umol/1). There were no changes in alkaline phosphatase, transaminases or gammaglutamyl transferase serum concentrations.
Transient Billrubin Rise after CPT-11 + Oxaliplatin
In each subsequent cycle, the same kinetics of bilirubin nse and fall were detected, but with some degree of hyperbilirubinemia at day 0 (range 23-31 umol/1) (Figure 1 ). On the seventh day after the first treatment cycle the patient developed grade 4 diarrhea and neutropenia, which resolved on day 12, and uneventful grade 4 neutropenia in all of the following 10 cycles. She was the only patient out of the seven patients treated at this same dose level to experience severe neutropenia. The CPT-11 dose was not reduced and she continues treatment with G-CSF support (300 ug s c, day 3-9). Analysis of serum bilirubin by alkaline methanolysis and HPLC (AM-HPLQ [8] showed a decrease in conjugated bilirubin concentrations, increased values of the relative amount of monoconjugates, with a decreased ratio of diconjugates to mono plus diconjugates (Table 1 ). This pattern is usually described in patients with Gilbert's syndrome [9] , Her CPT-11, SN-38 and SN-38G pharmacokinetic parameters showed a biliary index, as defined by Gupta et al. [3] of 8222 (Table 1) . She experienced a clinically meaningful minor response, with > 50% decrease in her baseline elevated tumor markers, still mantained after 13 cycles (10 months of treatment).
Patient B is a 63-year-old Greek man with massive liver involvement from colon cancer, treated with various fluoropyrimidine based regimens since September 1994, until progression in September 1996. He had familiar and personal antecedents of Gilbert's syndrome, with periodic asymptomatic increases in unconjugated bilirubin (range 40-78 umol/1). At the time of trial inclusion, his baseline bilirubine values were: total and conjugated bil 27 umol/1 / 9 umol/1 respectively.
He was treated with Oxaliplatin and CPT-11, given at 110 mg/m 2 and 200 mg/m 2 , respectively. At day 3, total and conjugated bilirubin increased respectively to 52 umol/1-19 umol/1, returning to baseline values by day 9. During the second treatment cycle he repeated the same pattern of serum bilirubin evolution (Figure 1) . His biliary index, obtained with area under the concentration-time curve (AUQ of CPT-11, SN-38 and SN-38G was 7106. He presented grade 4 neutropenia during the first cycle and grade 4 neutropenia and diarrhea in the second cycle (NCI CTQ ( Table 1) .
The patient discontinued chemotherapy treatment with stable disease, as a consequence of a jaundice caused by acute choledocholithiasis complicated with acute cholangitis after the second cycle, which was treated by endoscopic sphincterotomy. He returned to Greece, where subsequent treatment with Oxaliplatin and 5-FU has rendered a clinically meaningful stability lasting over five months. 
Discussion
We report two patients with antecedents of defective handling of unconjugated bilirubin, treated in a phase I trial with CPT-11 based chemotherapy. In all the cycles they evidenced severe toxicity (neutropenia and/or diarrhea).
The pharmacokinetic parameters in these two patients show a biliary index well above the 4000 thereshold value proposed by Gupta et al. As a very important interpatient variability exists for both SN-38 and SN-38G pharmacokinetics (70%-90%) [10] , this means that individual deficiency in SN-38 glucuronidation, as in Gilbert's syndrome, may be masked by the huge interindivual variation of the area under the curve values.
As far as we know, this phenomenon of severe and limiting toxicities in patients with hepatic conjugation deficiency treated with CPT-11 based chemotherapy, concurrent with a transient rise in bilirubin has not been previously reported.
ThTs "report matcrTwith the in vitro work of Iyer et al. [4] who demonstrated, in human liver microsomes, a significant correlation between SN-38 and bilirubin glucuronidation, which suggests that bilirubin UGT may also be glucuronidating SN-38.
Additional studies with HK293 cells transfected with specific human UGT isozymes showed that UGT* 1.1 is the isoform responsible for SN-38 glucuronidation.
Patients with Gilbert's syndrome , who have deficient UGT* 1.1 activity may be at an increased risk of CPT-11 toxicity, which is supported by our report.
The isolated transient bilirubin rise observed in these two patients led us to evaluate the kinetics of serum bilirubin after CPT-11 administration in all the patients of the ongoing Oxaliplatin/CPT-11 combination trial, as well as in a retrospective review of data from CPT-11 given as a single agent at the dose of 350 mg/m 2 every three weeks.
Our preliminary results [11] suggest that baseline serum bilirubin values are a valid predictor of severe CPT-11 linked toxicity episodes.
Oxaliplatin has not shown any evidence of hepatic toxicity in animals, nor in over 2500 treated patients at recommended doses [12, 13] . Moreover, its excretion is mostly urinary, with less than 1% excreted in feces over a five day determination period [14] . The presently described phenomenon is unlikely to be linked, therefore, to addition of Oxaliplatin to CPT-11, in the phase I-II experience.
The ongoing analysis and validation of serum bilirubin as an eventual predictive parameter of severe toxicity may improve the safety of CPT-11 based chemotherapy administration, and also be a tool to optimize individual patient dosing.
